Crohn Disease
- Body Composition and Disease Activity Correlate in Crohn Disease
- Early Ileocecal Resection in CD May Reduce Postoperative Complications
- Some Patients With Crohn Disease Require Ustekinumab Intensification Within First Year
- Etrolizumab Maintenance, but not Induction, Superior to Placebo in CD
- Consuming Ultra-Processed Foods May Affect Risk for Crohn Disease
- Ustekinumab IV Reinduction Efficacious in CD for Sub-Optimal Response to Maintenance
- Ustekinumab, Vedolizumab Both Efficacious for Highly Refractory Crohn Disease
- Race and Ethnicity May Affect Outcomes in Pediatric Crohn Disease
- Prophylactic Medications Decrease Recurrence Rates in Crohn Disease
- Off-Steroid Remission in CD Does Not Decrease Risk for Disease Progression
- Adalimumab Superior to Ustekinumab as First-Line Therapy for Crohn Disease
- Low fT3/fT4 Ratio Associates With Primary Nonresponse to Infliximab or Adalimumab
Conference Coverage
MORE MEETINGS
Clinical Tools
Powered by
Powered by 
